Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

BACKGROUND: Alectinib, a highly selective, central nervous system (CNS)-active anaplastic lymphoma kinase (ALK) inhibitor, demonstrated promising clinical activity in crizotinib-naïve and crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC). This phase 2 study evaluated the safety an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Shaw, Alice T., Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J., Cetnar, Jeremy, West, Howard, Camidge, D. Ross, Socinski, Mark A., Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H., Borghaei, Hossein, Gold, Kathryn A., Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ignatius Ou, Sai-Hong
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4752892/
https://ncbi.nlm.nih.gov/pubmed/26708155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00488-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados